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Abstract
Background—Hyponatremia has been associated with poor survival in many solid tumors and
more recently found to be of prognostic and predictive value in metastatic renal cell cancer
(mRCC) patients treated with immunotherapy.
Objective—To investigate the influence of baseline hyponatremia in mRCC patients treated with
targeted therapy in the International Metastatic Renal Cell Carcinoma Database Consortium.
Design, setting, and participants—Data on 1661 patients treated with first-line vascular
endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) targeted therapy
for mRCC were available from 18 cancer centers to study the impact of hyponatremia (serum
sodium level <135 mmol/l) on clinical outcomes.
Outcome measurements and statistical analysis—The primary objective was overall
survival (OS) and secondary end points included time to treatment failure (TTF) and the disease
control rate (DCR). The chi-square test was used to compare the DCR in patients with and without
hyponatremia. OS and TTF were estimated with the Kaplan-Meier method and differences
between groups were examined by the log-rank test. Multivariable logistic regression (for DCR)
and Cox regression (for OS and TTF) were undertaken adjusted for prognostic risk factors.
Results and limitations—Median OS after treatment initiation was 18.5 mo (95% confidence
interval [CI], 17.5–19.8 mo), with 552 (33.2%) of patients remaining alive on a median follow-up
of 22.1 mo. Median baseline serum sodium was 138 mmol/l (range: 122–159 mmol/l), and
hyponatremia was found in 14.6% of patients. On univariate analysis, hyponatremia was
associated with shorter OS (7.0 vs 20.9 mo), shorter TTF (2.9 vs 7.4 mo), and lower DCR rate
(54.9% vs 78.8%) (p < 0.0001 for all comparisons). In multivariate analysis, these effects remain
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significant (hazard ratios: 1.51 [95% CI, 1.26–1.80] for OS, and 1.57 [95% CI, 1.34–1.83] for
TTF; odds ratio: 0.50 [95% CI, 34–0.72] for DCR; adjusted p < 0.001). Results were similar if
sodium was analyzed as a continuous variable (adjusted p < 0.0001 for OS, TTF, and DCR).
Conclusions—This is the largest multi-institutional report to show that hyponatremia is
independently associated with a worse outcome in mRCC patients treated with VEGF- and
mTOR-targeted agents.
Keywords
Hyponatremia; Renal cell cancer; Anti-VEGF; Prognostic factors
1. Introduction
Renal cell cancer (RCC) is the sixth most common cancer in United States [1], accounting
for an estimated 64 770 new cases and 13 570 deaths in 2012. Patients can present with
metastatic disease or recur after nephrectomy. Currently, patients with advanced RCC are
stratified into three different risk groups based on the two prognostic models used most
[2,3]. These prognostic models take into account several baseline clinical and laboratory
values, and capture the natural history of metastatic RCC (mRCC).
Hyponatremia is one of the most common electrolyte disorders observed in hospitalized
patients [4], and it is probably highly underestimated. According to the studied populations
and the definition of hyponatremia, its reported frequency varies greatly, from <1% to >40%
[5]. Hyponatremia can be caused by either dilution of the serum sodium by excess retained
free water or by excessive sodium losses.
Hyponatremia has been associated with poor survival in several nonmalignant diseases, such
as congestive heart failure, liver cirrhosis, and infectious diseases (pneumonia, childhood
meningitis, necrotizing soft-tissue infection) [6–8]. Serum sodium has been analyzed in
mRCC patients treated with cytokines [9], and hyponatremia was found to be associated
with a worse outcome. Similar observations have been made in malignancies, such as
advanced hepatocellular carcinoma [10], advanced gastric cancer [11], advanced small cell
lung cancer [12], and localized RCC [13]. However, the role of hyponatremia in mRCC
patients treated with targeted therapies is not well defined. One study including 87 mRCC
patients treated with sunitinib or sorafenib showed that hyponatremia was significantly
associated with cancer-specific survival [14]. Since serum sodium levels are routinely
measured and, therefore, widely available most of the time, we sought to investigate the
association of hyponatremia on treatment outcomes in mRCC patients treated with
contemporary targeted therapies.
2. Methods
2.1. Patient population
The International Metastatic Renal Cell Cancer Database Consortium (IMDC) includes 20
academic cancer centers from Canada, the United States, Japan, South Korea, Singapore,
and Denmark. As of October 10, 2012, a total of 2370 patients who had received first-line
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targeted therapy between 2003 and 2012 were included. For this study, 1661 patients from
18 centers had baseline serum sodium level information readily available.
All patients were diagnosed with mRCC of any pathologic subtype with no prior vascular
endothelial growth factor (VEGF)-targeted therapy. Prior treatment with immunotherapy
(interleukin-2 or interferon) was allowed. The majority of patients were treated with a first-
line anti-VEGF agent: sunitinib, sorafenib, axitinib, bevacizumab, pazopanib, or tivozanib;
and a small proportion of patients were treated with mammalian target of rapamycin
(mTOR)-targeted agents: temsirolimus and everolimus.
Baseline demographic, clinical, and laboratory data, including those previously found to
have prognostic value, were collected retrospectively on all patients by using uniform
database templates to ensure consistent data collection [2]. Laboratory values were
standardized against institutional upper limit of normal (ULN) and lower limit of normal
(LLN) values when appropriate. Hyponatremia was defined as a serum sodium level <135
mmol/l, which is a widely used laboratory cut point. Outcome data on response rate, time to
treatment failure (TTF), and overall survival (OS) were collected from patient charts. This
study received institutional review board approval from each participating center.
2.2. Statistical analysis
The primary objective was to investigate whether baseline hyponatremia was associated
with OS, and secondary end points included TTF and the disease control rate (DCR). OS
was defined as time between targeted therapy initiation and the date of death, or it was
censored at the date of the last follow-up visit. TTF was defined as time between treatment
initiation and progression, drug cessation, death, or it was censored at the last follow-up
visit. Progression was determined according to clinical criteria that made continuation of
treatment impossible or radiographic criteria using the Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1. DCR included complete response, partial response, and stable
disease to targeted therapy per the RECIST criteria, which has been used as an inverse
measure of refractory disease (progressive disease as best response).
Patient and tumor characteristics, and DCR were compared between patients with and
without hyponatremia using the chi-square test. OS and TTF were estimated with the
Kaplan-Meier method and differences between groups were examined by the log-rank test.
Multivariable logistic regression (for DCR) and Cox regression (for OS and TTF) were
undertaken, adjusted for the IMDC prognostic risk factors [2]. Subgroup analyses were
performed according to the IMDC favorable-, intermediate-, and poor-risk groups,
respectively. Serum sodium level was also analyzed as a continuous variable in both
univariate and multivariable models adjusted for the IMDC prognostic risk factors.
All statistical computations were performed using SAS v.9.2 (SAS Institute Inc., Cary, NC,
USA) and a p value (two-sided) <0.05 was considered statistically significant.
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3. Results
3.1. Patient characteristics
Patient and disease characteristics at the initiation of targeted therapy, both of all patients (n
= 1661) and separated by hyponatremia status, are presented in Table 1. Most patients were
male (74%). Fifty-three percent of patients were older than 60 yr. The majority of patients
had clear cell histology (89%). Patients received one of the following VEGF-targeted
therapies: sunitinib (75%), sorafenib (17%), bevacizumab (4%), pazopanib (2%), tivozanib
(<1%), or axitinib (<1%); or mTOR-targeted therapies: temsirolimus (2%) and everolimus
(<1%). At the time of data analysis, 1428 patients (86%) had stopped the first-line targeted
therapy, and the median time on the first-line targeted therapy was 6.5 mo (range: 0.1–79.5
mo). The median OS after targeted treatment initiation was 18.5 mo (95% CI, 17.5–19.8
mo), with 552 patients (33.2%) remaining alive at last follow-up. The median follow-up
time for patients still alive was 22.1 mo (interquartile range: 10.8–37.3 mo).
A total of 243 patients (14.6%) had hyponatremia (baseline serum sodium level <135
mmol/l) at the initiation of targeted therapy. The median serum sodium level of the patient
population was 138 mmol/l (range: 122–159 mmol/l). Patients who had hyponatremia more
likely had low Karnofsky performance status (KPS) scores (<80) (p < 0.0001), sarcomatoid
pathology (p = 0.004), time from diagnosis to targeted therapy <1 yr (p = 0.001), time from
diagnosis to metastatic disease <1 yr (p = 0.006), low hemoglobin level (p < 0.0001), high
serum calcium level (p < 0.0001), elevated level of lactate dehydrogenase (LDH) (p =
0.001), high neutrophil levels (p < 0.0001), and high platelet count (p < 0.0001); but less
likely to have had prior nephrectomy or immunotherapy (p < 0.05) (Table 1).
3.2. Overall survival
When evaluating OS, we observed that patients with baseline hyponatremia had a
significantly shorter median OS compared to patients with normal serum sodium levels (7.0
vs 20.9 mo; hazard ratio [HR]: 2.31; 95% CI, 1.97–2.71; p < 0.0001) (Fig. 1A). After
adjusting for the IMDC prognostic risk factors, these results remained statistically
significant (adjusted HR: 1.51 [95% CI, 1.26–1.80; p < 0.0001]) (Table 2). Subgroup
analysis according to the IMDC risk groups showed that hyponatremic patients in the
intermediate- or poor-risk group had a significantly shorter median OS compared to patients
with normal serum sodium levels (10.9 vs 23.5 mo and 5.1 vs 10.0 mo, respectively) (HR:
1.80 [95% CI, 1.37–2.37; p < 0.0001] and 1.60 [95% CI, 1.29–1.99; p < 0.0001],
respectively). Patients in the favorable-risk group with or without hyponatremia had median
OS of 24.3 versus 41.1 mo, respectively (HR: 1.11 [95% CI, 0.45–2.71]), and this difference
was not statistically significant (p = 0.826) (Table 2). Of note, there were only 10 patients
with hyponatremia in the favorable group.
3.3. Time to treatment failure
Patients with baseline hyponatremia had also a significantly shorter median TTF compared
to patients with normal baseline serum sodium levels (2.9 vs 7.4 mo; HR: 1.96 [95% CI,
1.70–2.26; p < 0.0001]) (Fig. 1B). These results remained statistically significant after
adjusting for the IMDC risk factors on multivariate analysis (adjusted HR: 1.57 [95% CI,
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1.34–1.83; p < 0.0001]). Patients in the favorable-risk group with or without hyponatremia
had similar median TTF (12.7 vs 11.7 mo; HR: 1.16 [95% CI, 0.61–2.20; p = 0.644]).
However, in the intermediate- and poor-risk groups, hyponatremic patients had a
significantly shorter median TTF when compared to patients with normal serum sodium
level (4.1 vs 7.9 mo for the intermediate-risk group; and 2.3 vs 4.5 mo for the poor-risk
group) (HR: 1.69 [95% CI, 1.34–2.14; p < 0.0001] and 1.63 [95% CI, 1.32–2.01]; p <
0.0001], respectively) (Table 2).
3.4. Disease control rate
The associations between baseline serum sodium level and treatment response to targeted
therapy using RECIST criteria showed that hyponatremia was significantly associated with a
lower DCR. A total of 1320 (79%) patients were available for this analysis: 175 had
hyponatremia and 1145 had normal serum sodium levels. Patients with baseline
hyponatremia had a DCR of 55% compared to 79% in patients without hyponatremia (odds
ratio [OR]: 0.33 [95% CI, 0.24–0.46; p < 0.0001]) (Table 2). These results remained
statistically significant after adjusting for the IMDC risk factors (adjusted OR: 0.50 [95%
CI, 0.34–0.72; p = 0.0003]). Patients with hyponatremia also showed a reduced DCR
compared to patients with normal serum sodium level in each of the IMDC favorable,
intermediate, and poor groups (OR: 0.18 [95% CI, 0.04–0.79], 0.47 [95% CI, 0.27–0.80],
and 0.48 [95% CI, 0.29–0.78], respectively; p < 0.05).
3.5. Serum sodium concentration as a continuous variable
Baseline serum sodium level was an independent predictor of OS, TTF, and DCR when it
was analyzed as a continuous variable (Table 3). After covariate adjustment, the HR
associated with each 3-mmol/l decrease in serum sodium concentration was 1.19 (95% CI,
1.12–1.26) for mortality and 1.20 (95% CI, 1.14–1.27) for TTF (p < 0.0001). Decreased
serum sodium level was also related with a poorer DCR (adjusted OR: 0.77 [95% CI, 0.68–
0.87] per 3-mmol/l decrease; p < 0.0001). Results were also similar in subgroup analysis
according to the IMDC risk groups and when sodium level was analyzed as a continuous or
categorical variable (hyponatremia: yes or no).
4. Discussion
To our knowledge, this is the largest study to evaluate the association of hyponatremia on
outcome of mRCC patients treated with targeted agents. Hyponatremia was found to be
associated with a significant lower OS, TTF, and DCR at first staging evaluation in mRCC
patients receiving targeted therapy. Hyponatremic patients had 57% and 51% increase in the
risk of treatment failure or death, respectively. In addition, the 50% reduction in the odds of
disease control according to RECIST criteria suggests that patients with baseline
hyponatremia are more likely to be primary refractory to targeted therapy, suggesting an
aggressive underlying biology, or a poor tolerance to therapy leading to targeted therapy
dose reduction. Baseline hyponatremia was associated with other baseline unfavorable
prognostic features included in currently available prognostic scores (IMDC and Memorial
Sloan-Kettering Cancer Center), such as low KPS scores, time from diagnosis to targeted
therapy treatment <1 yr, low hemoglobin level, high serum calcium level, elevated LDH,
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high neutrophil levels, and high platelet count. However, it is important to point out that it
remained statistically significant even after adjusting for these known prognostic risk
factors, which captures the natural history and different survival patterns of mRCC patients
treated with targeted agents.
Hyponatremia has been shown to be a poor prognostic marker in a number of different
diseases, including liver cirrhosis, congestive heart failure (CHF), systemic infections, and
certain malignancies. In patients with end-stage liver disease, hyponatremia was related to
hemodynamic derangement, and was important in the potential development of hepatorenal
syndrome [15,16]. Based on this, sodium levels are included in the Model for End-Stage
Liver Disease score for the determination of liver transplant allocation [6].
Hyponatremia has also shown to be important in patients with CHF. In the Evaluation Study
of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)
trial, patients with persistent hyponatremia had a significantly increased risk of all-cause
mortality, rehospitalization from heart failure, and death [17]. Hyponatremia, along with a
combination of volume overload, water retention, and increased neurohormonal activation,
are thought to underlie the poor prognosis in these patients.
The presence of hyponatremia has also been shown to influence the prognosis of patients
with systemic infections, including pulmonary [7], cerebral, and necrotizing soft tissue
infections [18]. It is thought that inappropriate antidiuretic hormone (ADH) levels may be
partly responsible for the altered serum sodium levels. Progression of localized infection in
sepsis causes an increase in ADH level as well as adrenocortical insufficiency, resulting in
hyponatremia [19].
The mechanisms underlying the development of hyponatremia specifically in RCC patients
remains unclear. ADH may play a role as in other cancers [12], usually from an ectopic
production (syndrome of inappropriate antidiuretic hormone [SIADH]), although it can also
be a marker of burden of disease. SIADH is most commonly found in patients with lung
cancer (11–15%) [20], head and neck cancer (approximately 3%) [21], breast cancer, and, to
a lesser extent, in other types of malignancies. However, it is also possible to speculate that
patients with RCC may have some degree of renal dysfunction, especially those submitted to
nephrectomy, that could lead to hyponatremia. Cerebral salt wasting can also be involved in
the hyponatremia in cancer patients. This condition is most commonly seen in patients with
intracranial tumors that could impair the neurohypophysial pathways, resulting in increased
secretion of brain or atrial natriuretic peptides, which can lead to an inappropriate increased
renal excretion of sodium [22].
The incidence of hyponatremia in a general cancer population seems to be lower than that
observed in our mRCC patient population. In a series from Institut Jules Bordet, a
hyponatremia incidence of 3.7% was reported in patients with different types of
malignancies [5], whereas the incidence of hyponatremia in our mRCC cohort was 15%.
This difference could be partly explained by the mild renal impairment in mRCC patients,
since a significant proportion of them have undergone nephrectomy. Another possibility is
the more advanced stage in our cohort. Cancer patients with hyponatremia have also been
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shown to have an increased mortality compared to those with normal serum sodium levels
[5]. There is some evidence suggesting that the presence of hyponatremia in patients with
hepatocellular carcinoma is associated with a poorer prognosis with liver transplantation
[10]. A recent study examined the role of hyponatremia in the treatment of advanced
gastrointestinal stromal tumors with tyrosine-kinase inhibitor (imatinib) [23]. The authors
reported that low serum sodium at the start of imatinib treatment was a possible adverse
prognostic factor affecting OS. One of the largest series in a general cancer population
showed that hyponatremia was associated most commonly with altered ADH levels, which
could be secondary to a volume depletion, diuretic use, renal failure, or hypotonic fluid
intake [5]. Paraneoplastic syndromes, such as small cell lung cancers, are commonly
associated with ADH secretion [12]. Hyponatremia can also be a consequence of cancer
therapy or its side effects, such as diarrhea and vomiting [24]. However, in our patient
population, the cancer therapy probably did not play a role since the hyponatremia was
observed at baseline.
Our data demonstrate that hyponatremia in mRCC patients treated with anti-VEGF agents
had poor prognosis compared to patients with baseline normal serum sodium levels. These
data are in agreement with a British study in which a low preoperative sodium concentration
was found to be associated with reduced survival in patients with RCC undergoing
nephrectomy [13]. In our study, we have observed that hyponatremia was present in 15% of
patients at baseline. Similarly, another recent study, including only mRCC patients treated
with cytokines (two cohorts of 120 patients each), showed that hyponatremia was present in
14–20% of patients. In this same study, the authors observed that hyponatremic patients had
lower survival in multivariate analysis. Furthermore, hyponatremia was associated with lack
of response (by RECIST) to cytokines [9].
Hyponatremia in patients with mRCC could be also just a reflection of the baseline
comorbidities, such as renal failure, although prior data from our group showed that renal
function at therapy initiation does not adversely affect the efficacy of targeted therapy in
advanced RCC [25]. Several other comorbidities or factors may impair sodium homeostasis
such as ethnicity, CHF, hypertension, diabetes, cirrhosis, adrenal insufficiency,
hypothyroidism, diuretics, steroids, antiepileptics, selective serotonin reuptake inhibitors, or
alcohol use [26].
Our study has some limitations, which include the retrospective nature of our study and the
lack of evaluation of hyponatremia after starting the treatment for mRCC with targeted
therapy. It is unknown if aggressive treatment of baseline hyponatremia could eventually
alter the outcome of RCC patients treated with targeted therapy. Although hyponatremia was
prognostic, we could not determine if it was a predictive biomarker since all patients with
mRCC were treated with targeted therapies. Furthermore, we could not adjust our analysis
for other baseline factors potentially affecting sodium homeostasis; neither could we
evaluate the association with dose reductions of targeted agents. The strengths of our study
include the large number of included patients and the adjustment for the IMDC prognostic
risk criteria.
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5. Conclusions
In conclusion, we have shown that, in mRCC patients treated with targeted therapy, baseline
hyponatremia is associated with a poorer OS, TTF, and DCR. Hyponatremia may be a quick
and efficient method of stratifying patients beyond the IMDC criteria. Hyponatremia
deserves to be further investigated as a prognostic factor and evaluated for inclusion in
future prognostic tools.
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Fig. 1.
Kaplan-Meier plots of (A) overall survival and (B) time to treatment failure by
hyponatremia at the initiation of targeted therapy.
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Table 2
Associations of hyponatremia with overall survival, time to treatment failure, and disease control rate in all
patients who were treated with targeted therapy and in subgroup analysis according to the International
Metastatic Renal Cell Cancer Database Consortium risk groups
All patients (N = 1661) According to the IMDC risk groups*
Favorable
(n = 261)
Intermediate
(n = 870)
Poor
(n = 461)
Hyponatremia
Yes/No
Hyponatremia
Yes/No
Hyponatremia
Yes/No
Hyponatremia
Yes/No
OS
  No. 243/1418 10/251 88/782 137/324
  Median, mo 7.0/20.9 24.3/41.1 10.9/23.5 5.1/10.0
  Log-rank p value <0.0001 0.826 <0.0001 <0.0001
  HR (95% CI) 2.31
(1.97–2.71)
1.11
(0.45–2.71)
1.80
(1.37–2.37)
1.60
(1.29–1.99)
  Adjusted HR** (95% CI) 1.51(1.26–1.80)
– – –
  Adjusted p value** <0.0001 – – –
TTF
  No. 240/1405 10/250 87/775 135/320
  Mo, median 2.9/7.4 12.7/11.7 4.1/7.9 2.3/4.5
  Log-rank p value <0.0001 0.644 <0.0001 <0.0001
  HR (95% CI) 1.96
(1.70–2.26)
1.16
(0.61–2.20)
1.69
(1.34–2.14)
1.63
(1.32–2.01)
  Adjusted HR** (95% CI) 1.57(1.34–1.83)
– – –
  Adjusted p value** <0.0001 – – –
DCR
  No. 175/1145 9/205 66/641 93/244
  No. (%) with CR plus PR plus SD 96(55)/902(79) 6(67)/188(92) 42(64)/506(79) 46(49)/164(67)
  Chi-square p value <0.0001 0.023 0.005 0.003
  OR (95% CI) 0.33
(0.24–0.46)
0.18
(0.04–0.79)
0.47
(0.27–0.80)
0.48
(0.29–0.78)
  Adjusted OR** (95% CI) 0.50(0.34–0.72)
– – –
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All patients (N = 1661) According to the IMDC risk groups*
Favorable
(n = 261)
Intermediate
(n = 870)
Poor
(n = 461)
Hyponatremia
Yes/No
Hyponatremia
Yes/No
Hyponatremia
Yes/No
Hyponatremia
Yes/No
  Adjusted p value** 0.0003 – – –
CI = confidence interval; CR = complete response; DCR = disease control rate; HR = hazard ratio; IMDC = International Metastatic Renal Cell
Cancer Database Consortium; OR = odds ratio; OS = overall survival; PR = partial response; SD = stable disease; TTF = time to treatment failure.
*
Exclude 69 patients with an unknown risk group.
**Adjusted for the IMDC prognostic risk factors (time from diagnosis to targeted therapy <1 yr, Karnofsky performance status score <80, anemia,
neutrophilia, thrombocytosis, hypercalcemia).
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